MX2017006520A - Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico. - Google Patents

Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico.

Info

Publication number
MX2017006520A
MX2017006520A MX2017006520A MX2017006520A MX2017006520A MX 2017006520 A MX2017006520 A MX 2017006520A MX 2017006520 A MX2017006520 A MX 2017006520A MX 2017006520 A MX2017006520 A MX 2017006520A MX 2017006520 A MX2017006520 A MX 2017006520A
Authority
MX
Mexico
Prior art keywords
oxycodone
benzoic acid
conjugates
heteroaryl carboxylic
derivatives
Prior art date
Application number
MX2017006520A
Other languages
English (en)
Inventor
Guenther Sven
Bera Bindu
Mickle Travis
Kanski Jaroslaw
K Martin Andrea
Bera Sanjib
Original Assignee
Kempharm Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc * filed Critical Kempharm Inc *
Publication of MX2017006520A publication Critical patent/MX2017006520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a composiciones que comprende ácidos aril carboxílicos y, por ejemplo, NSAIDs, químicamente conjugados a oxicodona (4,5-a-epoxi-14-hidroxi-17-metilmorfinan-6- ona) para formar nuevos profármacos/composiciones de oxicodona, que incluyen benzoatos, salicilatos, propionatos, fenamatos, y acetatos, los cuales tienen un potencial reducido para abuso de oxicodona. La presente tecnología también proporciona métodos para tratar pacientes, kits farmacéuticos y métodos para sintetizar conjugados de la presente tecnología.
MX2017006520A 2014-11-25 2015-11-25 Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico. MX2017006520A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084216P 2014-11-25 2014-11-25
US201462084246P 2014-11-25 2014-11-25
PCT/US2015/062637 WO2016086113A1 (en) 2014-11-25 2015-11-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone

Publications (1)

Publication Number Publication Date
MX2017006520A true MX2017006520A (es) 2017-08-09

Family

ID=56075034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006520A MX2017006520A (es) 2014-11-25 2015-11-25 Acido benzoico, derivados de acido benzoico y conjugados de oxicodona de acido heteroaril carboxilico.

Country Status (18)

Country Link
US (3) US9850252B2 (es)
EP (1) EP3223819A4 (es)
JP (2) JP6400848B2 (es)
KR (2) KR20190049944A (es)
CN (1) CN106999486A (es)
AU (1) AU2015353502B2 (es)
BR (1) BR112017011069A2 (es)
CA (1) CA2967424C (es)
CL (1) CL2017001353A1 (es)
CO (1) CO2017005201A2 (es)
IL (1) IL252470B (es)
MX (1) MX2017006520A (es)
NZ (1) NZ731591A (es)
PH (1) PH12017500963A1 (es)
RU (1) RU2683317C2 (es)
SG (1) SG11201704178UA (es)
WO (1) WO2016086113A1 (es)
ZA (1) ZA201703154B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
JP6400848B2 (ja) 2014-11-25 2018-10-03 ケムファーム・インコーポレーテッド オキシコドンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体
US20200038383A1 (en) * 2016-10-14 2020-02-06 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
CN111107849B (zh) 2017-07-20 2024-03-29 苏州润鑫达泰生物医药有限公司 抗滥用长效释放阿片样前药
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB320749A (es)
US1731152A (en) 1925-10-27 1929-10-08 Firm C H Boehringer Sohn Process for the manufacture of derivatives of dihydrocodeinone or its substitution products
AT229496B (de) 1961-03-08 1963-09-25 Lannacher Heilmittel Verfahren zur Darstellung des neuen Nicotinsäureesters des Dihydrohydroxycodeinons
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
SE9003665D0 (sv) 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
GB9423542D0 (en) 1994-11-22 1995-01-11 Marples Brian A Pharmaceutical compounds
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
JP2004501067A (ja) 2000-01-28 2004-01-15 ローム　アンド　ハース　カンパニー 高められた特性をもつ医薬
NZ529661A (en) 2001-06-05 2006-03-31 Control Delivery Systems Sustained-release analgesic compounds
US7375082B2 (en) 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
EP1531844B1 (en) 2002-02-22 2014-08-20 Shire LLC Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
TW200500067A (en) 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US7230005B2 (en) 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
KR100915284B1 (ko) 2003-09-30 2009-09-03 샤이어 엘엘씨 과용 또는 남용을 예방하기 위한 제약 조성물
WO2005034859A2 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
AU2005252220B2 (en) 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7348430B2 (en) 2005-01-21 2008-03-25 Acura Pharmaceuticals, Inc. Production of opioid analgesics
AU2007238858A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
JP5371746B2 (ja) 2006-05-26 2013-12-18 ファーマコフォア， インコーポレイテッド フェノール性オピオイドの制御放出
US20080090771A1 (en) 2006-10-06 2008-04-17 Shire Llc Abuse-resistant hydrocodone compounds, compositions and methods of using the same
CA2709886C (en) 2007-12-17 2016-10-25 Mallinckrodt Inc. Processes for the production of (+)-"nal" morphinan compounds
CA2765836C (en) * 2009-07-02 2014-10-07 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (uk) 2009-07-02 2013-08-27 Кемфарм, Інк. Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань
US8623888B2 (en) 2009-07-15 2014-01-07 Mallinckrodt Llc 3-oxy-hydromorphone derivatives
RU2609412C2 (ru) * 2011-01-11 2017-02-01 Сигничер Терапьютикс, Инк. Композиции, содержащие расщепляемое ферментами пролекарство оксикодона
CN105749294A (zh) * 2011-10-26 2016-07-13 凯姆制药公司 氢吗啡酮的苯甲酸缀合物、苯甲酸衍生物缀合物和杂芳基羧酸缀合物、其前药、制备和使用方法
JP6400848B2 (ja) 2014-11-25 2018-10-03 ケムファーム・インコーポレーテッド オキシコドンの安息香酸、安息香酸誘導体及びヘテロアリールカルボン酸結合体

Also Published As

Publication number Publication date
CO2017005201A2 (es) 2017-08-31
CA2967424C (en) 2023-05-02
IL252470A0 (en) 2017-07-31
RU2683317C2 (ru) 2019-03-28
JP6400848B2 (ja) 2018-10-03
ZA201703154B (en) 2019-03-27
SG11201704178UA (en) 2017-06-29
RU2017122144A3 (es) 2018-12-26
JP2017535593A (ja) 2017-11-30
CN106999486A (zh) 2017-08-01
US10544153B2 (en) 2020-01-28
KR20170094249A (ko) 2017-08-17
EP3223819A1 (en) 2017-10-04
US20190048018A1 (en) 2019-02-14
EP3223819A4 (en) 2018-04-25
NZ731591A (en) 2018-06-29
PH12017500963A1 (en) 2017-10-18
CL2017001353A1 (es) 2018-01-05
IL252470B (en) 2019-08-29
AU2015353502B2 (en) 2018-09-27
KR20190049944A (ko) 2019-05-09
WO2016086113A1 (en) 2016-06-02
BR112017011069A2 (pt) 2018-07-10
US20180065975A1 (en) 2018-03-08
US9850252B2 (en) 2017-12-26
US10144740B2 (en) 2018-12-04
AU2015353502A1 (en) 2017-05-25
KR101976101B1 (ko) 2019-05-09
RU2017122144A (ru) 2018-12-26
CA2967424A1 (en) 2016-06-02
US20160168160A1 (en) 2016-06-16
JP2018199719A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
PH12017500963A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
MX362857B (es) Acido benzoico, derivados de acido benzoico y conjugados de acido heteroarilcarboxilico de hidromorfona, profarmacos, metodos de elaboracion y uso de los mismos.
MY153046A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
PH12017500828A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
PH12017500859A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
NZ728162A (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
NZ721645A (en) Compounds for use as gpr120 agonists
GEP201706725B (en) Compounds and compositions as inhibitors of mek
WO2015033228A3 (en) Compounds and use for treating cancer
WO2014170842A3 (en) Substituted alkyl carboxylic acid derivatives as gpr agonists
BR112018007673A2 (pt) ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos?
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
WO2015109017A3 (en) Deuterated no-releasing nonoate(oxygen-bound)chromene conjugates
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
WO2015151005A3 (es) Compuestos análogos del éster fenetílico del ácido caféico y su uso para la prevención y tratamiento de cáncer
RS20130270A1 (en) (S) -2-AMINO-3-CYCLOHEXYLPROPANIC ACID DERIVATIVES, THEIR PRODUCTION AND USE
WO2016196256A3 (en) Non-aromatic difluoro analogues of resorcylic acid lactones
MX369303B (es) Nuevos complejos de agomelatina y de acidos sulfonicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MY176807A (en) Novel indazole compounds and a process for the preparation thereof